In Vitro and In Vivo Activity of an Organic Tellurium Compound on Leishmania (Leishmania) chagasi

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Pimentel, Isabella Aparecida Salerno ^a   Paladi, Carolina de Siqueira ^a   Katz, Simone ^a   Júdice, Wagner Alves de Souza ^b   Cunha, Rodrigo L O R ^c   Barbiéri, Clara Lúcia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

^c UNIVERSIDADE FEDERAL DO ABC   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 CHLORO 3 [CHLOROMETHYLIDENE] 1 OXA 2 TELLURASPIRO[3.5]NON 2 YL]PHENYL METHYL ETHER; CATHEPSIN B; MEGLUMINE ANTIMONATE; RF 07; TELLURIUM DERIVATIVE; UNCLASSIFIED DRUG;

AMASTIGOTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HAMSTER; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA CHAGASI; LEISHMANIASIS; LEISHMANICIDAL ACTIVITY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARASITE LOAD; TREATMENT RESPONSE;

ANIMALS; ANTIPROTOZOAL AGENTS; CATHEPSIN B; CRICETINAE; FEMALE; LEISHMANIA; MESOCRICETUS; MICE; MICE, INBRED BALB C; ORGANOMETALLIC COMPOUNDS; PARASITIC SENSITIVITY TESTS; PROTEOLYSIS; SPIRO COMPOUNDS; TOXICITY TESTS;

ANIMALIA; CRICETINAE; LEISHMANIA DONOVANI CHAGASI; MESOCRICETUS AURATUS;

EID: 84868684782     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048780     Document Type: Article

References (39)

1. Nascimento ELT, Martins DR, Monteiro GR, Barbosa JD, Ximenes MFFM, et al. (2008) Forum: geographic spread and urbanization of visceral leishmaniasis in Brazil. Postscript: new challenges in the epidemiology of Leishmania chagasi infection. Cad Saúde Pública 24: 2964-2967.
2. WHO (2010) Control of leishmaniasis. Report of the Expert Committee. World Health Organization. Tech Rep Ser 949: 1-186.
3. Goto H, Lindoso JA, (2010) Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8: 419-433.
4. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, et al. (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347: 1739-1746.
5. Soto J, Arana BA, Toledo J, Rizzo N, Veja JC, et al. (2004) Miltefosine for New World cutaneous leishmaniasis. Clin Infect Dis 38: 1266-1272.
6. Polonio T, Efferth T, (2008) Leishmaniasis: drug resistance and natural products (review). Int J Mol Med 22: 277-286.
7. Arias JR, Monteiro PS, Zicker F, (1996) The reemergence of visceral leishmaniais in Brazil. Emerg Infect Dis 2: 145-146.
8. Murray HW, (2001) Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 45: 2185-2197.
9. Seifert K, (2011) Structures, targets and recent approaches in anti-leishmanial drug discovery and development. Open Med Chem J 5: 31-39.
10. Sen R, Chatterjee M, (2011) Plant derived therapeutics for the treatment of Leishmaniasis. Phytomedicine 18: 1056-1069.
11. Tempone AG, Martins de Oliveira C, Berlinck RG, (2011) Current approaches to discover marine antileishmanial natural products. Planta Med 77: 572-585.
12. Tiuman TS, Santos AO, Ueda-Nakamura T, Filho BPD, Nakamura CV, (2011) Recent advances in leishmaniasis treatment. Int J Infect Dis 15: 525-532.
13. Ba LA, Döring M, Jamier V, Jacob C, (2010) Tellurium: an element with great biological potency and potential. Org Biomol Chem 8: 4203-4216.
14. Cunha R.L.O.R., Gouvea IE, Juliano L, (2009) A glimpse on biological activities of tellurium compounds. An Acad Bras Cienc 81: 393-407.
15. Sredni B, (2012) Immunomodulating tellurium compounds as anti-cancer agents. Semin Cancer Biol 22: 60-69.
16. Tiekink ER, (2012) Therapeutic potential of selenium and tellurium compounds: Opportunities yet unrealised. Dalton Trans. 41: 6390-6395.
17. Urig S, Becker K, (2006) On the potential of thioredoxin reductase inhibitors for cancer therapy. Seminars Cancer Biol 16: 452-465.
18. Wieslander E, Engman L, Svensjö E, Erlansson M, Johansson U, et al. (1998) Antioxidative properties of organotellurium compounds in cell systems. Biochem Pharmacol 55: 573-584.
19. Cunha R.L.O.R., Urano ME, Chagas JR, Almeida PC, Bincoletto C, et al. (2005) Tellurium-based cysteine protease inhibitors: evaluation of novel organotellurium(IV) compounds as inhibitors of human cathepsin B. Bioorg Med Chem Lett. 15: 755-760.
20. Abodanza TS, Oliveira CR, Barbosa CMV, Pereira FEG, Cunha R.L.O.R., et al. (2008) Bcl-2 expression and apoptosis induction in human HL-60 leukaemic cells treated with a novel organotellurium (IV) compound RT-04. Food Chem Toxicol 46: 2540-2545.
21. Persike DS, Cunha R.L.O.R., Juliano L, Silva IR, Rosim FE, et al. (2008) Protective effect of the organotelluroxetane RF-07 in pilocarpine-induced status epilepticus. Neurobiol Dis 31: 120-126.
22. Somanna A, Mundodi V, Gedamu L, (2002) Functional analysis of cathepsin B-like cysteine proteases from Leishmania donovani complex. Evidence for the activation of latent transforming growth factor beta. J Biol Chem 277: 25305-25312.
23. Mundodi V, Kucknoor AS, Gedamu L, (2005) Role of Leishmania (Leishmania) chagasi amastigote cysteine protease in intracellular parasite survival: studies by gene disruption and antisense mRNA inhibition. BMC Mol Biol 6: 3.
24. Lima CBC, Arrais-Silva WW, Cunha R.L.O.R., Giorgio S, (2009) A novel organotellurium compound (RT-01) as new antileishmanial agent. Korean J Parasitol 47: 213-218.
25. Barbiéri CL, Doine AI, Freymuller E, (1990) Lysosomal depletion in macrophages from spleen and foot lesions of Leishmania-infected hamster. Exp Parasitol 71: 218-228.
26. Zeni G, (1999) Chieffi A, Cunha R.L.O.R., Zukerman-Schpector J, Stefani HA, et al (1999) Addition reaction of p-methoxyphenyltellurium trichloride to 3-hydroxy alkynes. Organometallics 18: 803-806.
27. Zamboni DS, Rabinovitch M, (2003) Nitric oxide partially controls Coxiella burnetii phase II infection in mouse primary macrophages. Infect Immun 71: 1225-1233.
28. Dutta A, Bandyopadhyay S, Mandal C, Chatterjee M, (2005) Development of a modified MTT assay for screening antimonial resistant field isolates of Indian visceral leishmaniasis. Parasitol Int 54: 119-122.
29. Lima HC, Bleyenberg JA, Titus RG, (1997) A simple method for quantifying Leishmania in tissues of infected animals. Parasitol Today 13: 80-82.
30. Cotrin SS, Puzer L, de Souza Judice WA, Juliano L, Carmona AK, et al. (2004) Positional-scanning combinatorial libraries of fluorescence resonance energy transfer peptides to define substrate specificity of carboxydipeptidases: assays with human cathepsin B. Anal Biochem. 335: 244-252.
31. De Muylder G, Ang KK, Chen S, Arkin MR, Engel JC, et al. (2011) A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl Trop Dis 5: e1253.
32. Freitas-Junior LH, Chatelain E, Kim HA, Siqueira-Neto JL, (2012) Visceral leishmaniasis treatment: What do we have, what do we need and how to deliver it? Int J Parasitol 2: 11-19.
33. Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, Katz S, Barbiéri CL, et al. (2009) Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother 63: 365-368.
34. Sunduru N, Nishi, Palne S, Chauhan PM, Gupta S, (2009) Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines. Eur J Med Chem 44: 2473-2481.
35. Berman JD, (1997) Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24: 684-703.
36. Campbell TW (2004) Clinical Chemistry of Mammals: Laboratory Animals and Miscellaneous Species. In: Thrall MA, Baker DC, Campbell TW, DeNicola DB, Fettman MJ, Lassen ED Rebar A, Weiser G, editors. Veterinary Hematology and Clinical Chemistry. Philadelphia: Lippcott Williams & Wilkins, 463-478.
37. Cunha R.L.O.R., Gouvêa IE, Feitosa GP, Alves MFM, Brömme D, et al. (2009) Irreversible inhibition of cathepsins B, L, S and K by hypervalent tellurium compounds. Biol Chem 390: 1205-1212.
38. Croft SL, Sundar S, Fairlamb AH, (2006) Drug resistance in leishmaniasis. Clin Microbiol Reviews 19: 111-126.
39. Albeck A, Weitman H, Sredni B, Albeck M, (1998) Tellurium compounds: Selective inhibition of cysteine proteases and model reaction with thiols. Inorg Chem 37: 1704-1712.